Vaxil has developed the FIRST EVER ANTIBODIES designed for the production against signal peptide domains of renowned cancer antigens. Utilizing VaxHit, Vaxil can isolate Signal Peptide epitopes that are used as antigens for generating more specific antibodies against known and novel targets. SPmAb2.1 and SPmAb-6 are the first to have been developed, both anti-MUC1. ucts as well as companion diagnostics.
Vaxil’s found that the signal peptide epitopes can be displayed on the tumor cell surface independently of MHC presentation, thus, making them candidates for the development of an efficient antibody production platform for therapy and diagnostics.
VAXIL – Creating the ideal immunotherapy
Inducing a Broad
Cancer ResistanceLearn More
Immune ResponseLearn More
Cancer Stem CellsLearn More
First Ever SP-Specific
Antibody PlatformLearn More
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is its ImMucin™ lead immunotherapy product.